PT - JOURNAL ARTICLE AU - Zaid Almarzooq AU - Manan Pareek AU - Lauren Sinnenberg AU - Muthiah Vaduganathan AU - Mandeep R. Mehra TI - Nine contemporary therapeutic directions in heart failure AID - 10.1136/heartasia-2018-011150 DP - 2019 Mar 01 TA - Heart Asia PG - e011150 VI - 11 IP - 1 4099 - http://heartasia.bmj.com/content/11/1/e011150.short 4100 - http://heartasia.bmj.com/content/11/1/e011150.full SO - Heart Asia2019 Mar 01; 11 AB - The global burden of heart failure has continued to increase dramatically with 26 million people affected and an estimated health expenditure of $31 billion worldwide. Several practice-influencing studies were reported recently, bringing advances along many frontiers in heart failure, particularly heart failure with reduced ejection fraction. In this article, we discuss nine distinct therapeutic areas that were significantly influenced by this scientific progress. These distinct areas include the emergence of sodium-glucose cotransporter-2 inhibitors, broadening the application of angiotensin-neprilysin inhibition, clinical considerations in therapy withdrawal in those patients with heart failure that ‘recover’ myocardial function, benefits of low-dose direct oral anticoagulants in sinus rhythm, targeted therapy for treating cardiac amyloidosis, usefulness of mitral valve repair in heart failure, the advent of newer left ventricular assist devices for advanced heart failure, the role of ablation in atrial fibrillation in heart failure, and finally the use of wearable defibrillators to address sudden death.